Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 1.00 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.86 |
| ▸ | CX3CR1 | P49238 | 2/20 | 0.67 |
| ▸ | CCR7 | P32248 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842193 | 0.93 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1CCR7 | |
| SCHEMBL13712919 | 0.90 | CXCR2 (0.81) | CXCR2CXCR1CX3CR1CCR7 | |
| SCHEMBL4482409 | 0.89 | CXCR2 (0.80) | CXCR2CXCR1CX3CR1CCR7 | |
| SCHEMBL4483211 | 0.87 | CXCR2 (0.77) | CXCR2CXCR1CX3CR1CCR7 | |
| SCHEMBL6866821 | 0.85 | CXCR2 (0.74) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL5035710 | 0.83 | CXCR2 (0.74) | CXCR2CXCR1CX3CR1CCR7 | |
| SCHEMBL6859607 | 0.83 | CXCR2 (0.72) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL6859529 | 0.83 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL842319 | 0.83 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL4488684 | 0.83 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806273-B1 | 5-THIO-THIAZOLO(4,5-D)PYRIMIDIN-7-YL DERIVATIVES; CHEMOKINE RECEPTOR (ESPECIALLY CXCR2) ACTIVITY MODULATORS | ASTRAZENECA AB (SE) | 2004-10-19 | — | — | US | claimed |
| EP-1104425-B1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | claimed |
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| EP-1543013-B1 | 5-[[(2,3-Difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one monosodium salt as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| EP-1543013-B1 | 5-[[(2,3-Difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one monosodium salt as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20060100221-A1 | Novel compound | ASTRAZENECA AB (SE) | 2006-05-11 | — | — | US | disclosed |
| US-6806273-B1 | 5-THIO-THIAZOLO(4,5-D)PYRIMIDIN-7-YL DERIVATIVES; CHEMOKINE RECEPTOR (ESPECIALLY CXCR2) ACTIVITY MODULATORS | ASTRAZENECA AB (SE) | 2004-10-19 | — | — | US | disclosed |
| EP-1104425-B1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| EP-1104425-A1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009511-A1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100221-A1 | Novel compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885CXCR1 274/4885CX3CR1 2854/4885 |
| US-20080306262-A1 | Novel Compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885CXCR1 274/4885CX3CR1 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.